Description

NEO-MERCAZOLE 10 MG (1X130)

Indications

NEO-MERCAZOLE, containing the active ingredient carbimazole, is primarily indicated for the treatment of hyperthyroidism, particularly in patients with Graves’ disease. It is also used to prepare patients for thyroid surgery or radioactive iodine therapy, helping to reduce thyroid hormone levels prior to these interventions. The medication is effective in managing symptoms associated with hyperthyroidism, such as palpitations, weight loss, and anxiety.

Mechanism of Action

Carbimazole is a thionamide that works by inhibiting the synthesis of thyroid hormones. It achieves this by blocking the enzyme thyroperoxidase, which is essential for the iodination of tyrosine residues in thyroglobulin, a precursor to thyroid hormones. By inhibiting this enzyme, carbimazole decreases the production of thyroxine (T4) and triiodothyronine (T3), leading to a reduction in circulating thyroid hormone levels. This mechanism helps alleviate the symptoms of hyperthyroidism and restore normal thyroid function.

Pharmacological Properties

NEO-MERCAZOLE is rapidly absorbed from the gastrointestinal tract, with peak plasma concentrations typically occurring within 1 to 2 hours after oral administration. The drug is metabolized in the liver to its active form, methimazole, which has a longer half-life than carbimazole itself. The elimination half-life of carbimazole is approximately 6 hours, while methimazole can last up to 12 hours. The drug is primarily excreted in the urine, with a small amount eliminated in feces. The pharmacokinetics of carbimazole may be altered in patients with liver impairment, necessitating careful monitoring and potential dose adjustments.

Contraindications

NEO-MERCAZOLE is contraindicated in individuals who have a known hypersensitivity to carbimazole or any of its components. It should also be avoided in patients with severe liver dysfunction or a history of agranulocytosis associated with thionamide use. Additionally, it is not recommended for use during pregnancy unless the potential benefits outweigh the risks, particularly during the first trimester, as it may affect fetal thyroid function.

Side Effects

Common side effects of NEO-MERCAZOLE include rash, pruritus, and gastrointestinal disturbances such as nausea and vomiting. More serious side effects, though rare, can occur. These include agranulocytosis, which is a potentially life-threatening condition characterized by a dangerously low white blood cell count, as well as liver dysfunction, hepatitis, and allergic reactions. Patients should be monitored regularly for signs of these adverse effects, particularly during the initial months of therapy.

Dosage and Administration

The recommended starting dose of NEO-MERCAZOLE for adults is typically 15 to 40 mg per day, divided into two or three doses. Once thyroid hormone levels are stabilized, the dose may be gradually reduced to a maintenance dose of 5 to 15 mg per day. For children, the dosage is usually calculated based on body weight, with a common range being 0.5 to 1 mg/kg/day. It is important for patients to adhere to the prescribed dosage and to consult their healthcare provider before making any changes to their medication regimen.

Interactions

NEO-MERCAZOLE may interact with several other medications, which can affect its efficacy and safety. Notably, the use of anticoagulants such as warfarin may require careful monitoring, as carbimazole can enhance the anticoagulant effect. Additionally, certain medications that affect liver enzymes, such as phenobarbital or rifampicin, may alter the metabolism of carbimazole, potentially leading to decreased effectiveness. Patients should inform their healthcare provider of all medications and supplements they are taking to avoid potential interactions.

Precautions

Before starting treatment with NEO-MERCAZOLE, patients should be thoroughly evaluated for any underlying health conditions, particularly liver disease or blood disorders. Regular blood tests to monitor white blood cell counts and liver function are recommended, especially during the first few months of therapy. Patients should be advised to report any signs of infection, such as fever or sore throat, as these may indicate agranulocytosis. It is also essential to inform patients about the potential risks associated with the medication and the importance of adhering to follow-up appointments.

Clinical Studies

Numerous clinical studies have demonstrated the efficacy of carbimazole in the management of hyperthyroidism. A systematic review published in the Journal of Clinical Endocrinology & Metabolism indicated that carbimazole effectively reduces thyroid hormone levels and alleviates symptoms in patients with Graves’ disease. Another study found that carbimazole is comparable to methimazole in terms of efficacy and safety, making it a viable option for patients requiring antithyroid therapy. Long-term studies have also suggested that carbimazole can lead to remission in a significant proportion of patients, particularly when used as part of a comprehensive treatment plan.

Conclusion

NEO-MERCAZOLE 10 MG is an effective treatment option for individuals with hyperthyroidism, particularly those with Graves’ disease. Its mechanism of action, pharmacological properties, and clinical efficacy make it a valuable tool in managing thyroid hormone levels. However, careful monitoring for side effects and interactions is essential to ensure patient safety and treatment success. As with any medication, it is crucial for patients to work closely with their healthcare provider to determine the most appropriate treatment plan for their individual needs.